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T
he unique optical and electromag-
netic properties of plasmonic nano-
materials have generated interest in
using these materials for a variety of appli-
cations in medicine ranging from clinical
diagnostics and imaging to targeted tumor
therapy.15 The strong scattering and ab-
sorption properties of plasmonic nanoma-
terials have led to the development of
highly sensitive plasmonic biosensors for
detecting glucose from bioﬂuids, epidermal
growth factor receptors (EGFR) on human
cancer cells, amyloid beta from blood, and
cerebrospinal ﬂuid in Alzheimer's Disease,
and human papilloma virus DNA.612 For
therapeutic applications, the ability of plas-
monic nanomaterials to absorb speciﬁc wa-
velengths of light and eﬃciently generate
heat through the surface plasmon reso-
nance (SPR) eﬀect has been exploited for
localized ablation of solid tumors, as well as
for milder subablative heating to transiently
damage nontumor endothelial cells or en-
hance delivery of therapeutic cargoes.1318
Collectively, these studies have demonstrated
the potential for plasmonic photothermal
therapy to impact a variety of pathophysio-
logical processes such as tumor growth and
angiogenesis. The advantages of polyethy-
lene glycol-coated gold nanorods (PEG-NRs)
in particular include their long-term stabi-
lity, minimal cytotoxicity, and ability to be
geometrically tuned to absorb speciﬁc wa-
velengths of NIR light.16,17,1923 In preclini-
cal models, PEG-NRs passively accumulate
in tumors, eﬃciently absorb NIR light, and
generate localized heat through the SPR
eﬀect. To date, the therapeutic potential of
PEG-NR-mediated photothermal ablation as
well as subablative heating for recruitment
of therapeutic cargoes has been demon-
strated in both genetically engineered and
xenograft animal models.13,16,17,2224
One limitation of approaches involving
NIR light delivered by an external device is
the limited penetration depth of NIR light
due to the optical absorption and scattering
properties of biological tissue, which has
restricted therapeutic studies to superﬁcial
tumors located near the skin surface.25 For
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ABSTRACT Plasmonic nanomaterials including gold nanorods are eﬀective
agents for inducing heating in tumors. Because near-infrared (NIR) light has
traditionally been delivered using extracorporeal sources, most applications of
plasmonic photothermal therapy have focused on isolated subcutaneous tumors.
For more complex models of disease such as advanced ovarian cancer, one of the
primary barriers to gold nanorod-based strategies is the adequate delivery of NIR
light to tumors located at varying depths within the body. To address this
limitation, a series of implanted NIR illumination sources are described for the speciﬁc heating of gold nanorod-containing tissues. Through computational
modeling and ex vivo studies, a candidate device is identiﬁed and validated in a model of orthotopic ovarian cancer. As the therapeutic, imaging, and
diagnostic applications of plasmonic nanomaterials progress, eﬀective methods for NIR light delivery to challenging anatomical regions will complement
ongoing eﬀorts to advance plasmonic photothermal therapy toward clinical use.
KEYWORDS: gold nanorods . implanted illumination . near-infrared . photothermal therapy . cancer
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solid tumors positioned in deeper, more anatomically
challenging regions and distributed over larger areas,
such as advanced ovarian cancer, it would be advanta-
geous to have NIR light delivery systems capable of
providing suﬃcient energy to elicit the SPR eﬀect
within these deeper and spatially distributed tumor
environments. Several eﬀorts to deliver light internally
for applications such as photodynamic therapy have
focused on optical ﬁber technologies, which direct a
point source of light upon target tissues.2528 For laser-
induced interstitial therapy (LITT) protocols, surface-
and volume-scattering applicators have been devel-
oped to homogeneously scatter light after catheter-
guided insertion directly into individual tumors.2931
By contrast, for scenarios requiring broader NIR illumi-
nation of multiple target tissues simultaneously, in-
cluding tissues that may not be visible to the human
eye or accessible by catheter, a source providing
contiguous illumination over a larger surface area
would be beneﬁcial.
In this study, a potential strategy combining
systemically delivered plasmonic nanomaterials with
locally implanted NIR illumination sources is described.
A series of biocompatible, implanted illumination
devices are characterized through computational
modeling, ex vivo ﬂuence rate and thermographic
measurements, and in vivo thermographic proﬁling.
Two illumination devices were capable of heating
solutions of PEG-NRs in a dose-dependent manner,
and one of these devices was further validated by
in vivo imaging and thermography. In animal models
of orthotopic ovarian cancer pretreated with PEG-NRs,
delivery of NIR light via the implanted device selec-
tively elevated the temperature of ovarian tumors
relative to background tissue without generating irre-
versible tissue damage and enhanced the delivery of
diagnostic and therapeutic agents. Collectively, these
data illustrate that synergies between plasmonic nano-
materials and novel NIR illumination methods can
achieve selective and tolerable photothermal eﬀects
in complex anatomical environments.
RESULTS AND DISCUSSION
PEG-NRs were prepared from stock CTAB-coated
gold nanorods tominimize toxicity and extend particle
circulation time as previously described. (Figure 1,
left)16,17 Transmission electron microscopy (TEM)
images revealed the PEG-NR dimensions to be 41 nm
in length and 10 nm in width for an aspect ratio of
4.1 (Figure 1, left). The surface plasmon resonance
(SPR) peak absorbance of PEG-NRs was 808 nm in
accordance with previously observed measurements
(Figure 1, left). ImplantedNIR illumination deviceswere
composed of silica rods and ﬁber optic meshes
(Figure 1, center). Silica rods were designed with vary-
ing geometric parameters such as diameter, length,
and tip tapering, treated to have uniform surface
diﬀusivity along the rod, and joined with an SMA
ﬁber-optic connector to interface with a continuous
810 nm NIR laser source. To provide a ﬂexible alter-
native to the silica rods, ﬁber optic meshes consisting
of submillimeter ﬁbers encased in adhesive medical-
grade silicone were prepared. Fibers were treated by
an optomechanical scoring process prior to encase-
ment to alter the total internal reﬂection at distinct
locations and thereby permit NIR light emission along
the length of the ﬁbers. For each device, ﬂuence
ratedistance relationships were computed for input
currents ranging from 9.0 to 13.0 A (Figure 1, center).
The combination of systemic PEG-NRs and implantedNIR
devices was investigated as a strategy to achieve photo-
thermal heating in deep tumor nodules (Figure 1, right).
The abdominal cavity consists of organs and biolo-
gical tissues with varying optical and geometric prop-
erties contained within a conﬁned anatomical com-
partment. To develop a quantitative framework for
understanding NIR illumination in the abdominal cav-
ity and thereby assess the feasibility of the implanted
NIR devices, a three-dimensional solid model incorpora-
ting the liver, spleen, stomach, kidney, large and small
intestine, and skin was developed (Supporting Infor-
mation, Figure 1, Figure 2a). For modeling simulations,
Figure 1. First component for plasmonic photothermal heating of intraperitoneal tumors consists of polyethylene glycol-
coated gold nanorods (PEG-NRs), which are characterized by TEM imaging and optical absorbance. (Left panel) PEG-NRs with
an aspect ratio of 4.1 display a peak surface plasmon resonance (SPR) at 808 nm. Scale bar: 20 nm. (Center panel) Classes of
implanted NIR devices include silica rods and ﬂexible meshes encased in silicone. Generalized ﬂuence ratedistance
relationship for several input currents (Io) of an implanted NIR device. (Right panel) The combination of systemically
administered PEG-NRs and implanted NIR illumination permits plasmonic photothermal therapy for intraperitoneal tumors.
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abdominal organs were assigned approximate indices
of refraction, scattering coeﬃcients, and absorption
coeﬃcients based on values obtained from the litera-
ture (Supporting Information, Table 1). Previous com-
putational models developed in our lab applied ﬁnite
element simulations to approximate photothermal
heating of gold nanorod-containing subcutaneous
tumors using the bioheat transfer equation.16 While
the current model describes NIR light distribution in
nontumor tissues within the abdominal cavity, future
models incorporating tumor tissue elements, absorp-
tion coeﬃcients dependent on gold nanorod tissue
content, and biophysical heat transfer equations will
be useful for providing a more detailed description of
plasmonic photothermal heating in the abdominal
cavity. The current deterministic model predicts that
most of the emitted NIR light focuses on regions
containing the intestine, liver, and spleen within the
abdominal cavity with lambertian, or diﬀusely re-
ﬂected, illumination along the silica rod (Figure 2a). In
comparison, with a lambertian proﬁle along the ﬂex-
ible mesh, the model predicts an enhanced, more
uniform transmittance within the abdominal cavity
due to increased surface area relative to the silica rod
(Figure 2a). Importantly, simulations using this anato-
mically based model predicted the limitations of NIR
light penetration due to tissue absorption and scatter-
ing. For example, at the interface of the silica rod and
abdominal organs with an input power of 1 W along
the device, the model predicts a peak ﬂuence rate of
1.35 103 W/m2, while at a distance 8mm deep to the
device, the peak ﬂuence rate decays to 5.9 102W/m2
(Figure 2a). Similarly, at the interface of the ﬂexible
mesh and abdominal organs, the peak ﬂuence rate is
estimated to be 3.0  103 W/m2, and the peak ﬂuence
rate decays to 7.3  102 W/m2 at a depth of 8 mm
(Figure 2a). The depth-dependent decay observed is
consistent with tissue absorption and scattering and
suggests that the model parameters approximate to a
ﬁrst order the in vivo environment.
To validate and reﬁne model predictions for the
silica rods and ﬂexible mesh, ﬂuence rate was calcu-
lated at multiple distances and input currents for six
distinct implanted NIR devices (Figure 2b). Consistent
with the model, ﬂuence rate decreased approximately
as the square of the distance between the device and
detector plate when measured in an air medium
(Figure 2c). As the input current from the laser was
increased, a linear increase in ﬂuence rate was ob-
served at the surface of each implanted device, high-
lighting the ability to precisely tune the NIR emission
from the devices to achieve the desired level of
photothermal heating in vivo (Figure 2c). In contrast
to the model predictions, the peak ﬂuence rate mea-
sured for the ﬂexible mesh surface (∼500 W/m2) did
not reach the maximal surface ﬂuence rate of 3.0 
103 W/m2 predicted by the model. Limitations related
to the material properties and device fabrication likely
contributed to the diﬀerence and suggest that future
models could be reﬁned by incorporating speciﬁc
Figure 2. (a) Fluence rate simulation in the abdominal cavity with two implanted NIR devices at a length up to 8 mm depth
from the skin surface. (b) Photographs of implanted NIR devices investigated include silica rods (devices 15) and mesh.
(c) Fluence rates from a representative silica rod device for variable input currents ranging from 9.0 to 13.0 A and distances
from source ranging from 0 to 4 cm. (d) Fluence ratedistance curves obtained at 13.0 A input current for multiple models
(devices 15; mesh) and spatial orientations of implanted NIR devices.
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physical properties of the device in addition to tissue
properties. Finally, surface ﬂuence rate was highly de-
pendent on the geometry of the device and spanned
several orders of magnitude (4  103 W/m2 to 2 
101 W/m2) (Figure 2d).
On the basis of the surface ﬂuence rate measure-
ments, we next assessed whether our devices pos-
sessed diﬀering capacities to photothermally heat
PEG-NRs. In an ex vivo setting, multiple concentrations
of PEG-NRs in PBS were subjected to continuous NIR
laser irradiation (810 nm) dispersed by each implanted
device, and the temperature of PEG-NR solutions was
continuously monitored via infrared thermography
(Figure 3a,b). Several distinct patterns of photothermal
heating were observed, which are denoted as (1)
nonspeciﬁc, (2) PEG-NR-dependent, and (3) ineﬃcient.
Owing to elements of device construction that resulted
in a greater localized concentration of laser energy at
the device tip (device 3), nonspeciﬁc devices led to
temperature elevations in both PEG-NR- and PBS con-
trol solutions (Figure 3c,d, Supporting Information,
Figure 2). Conversely, devices with ineﬃcient heating
failed to yield an appreciable rise in temperature of
PEG-NR solutions at approximately physiologic PEG-NR
concentrations (Figure 3c,d, Supporting Information,
Figure 2). A subset of implanted devices investigated,
however, was observed to selectively elevate the
temperature of PEG-NR solutions in a concentration-
dependent manner while failing to signiﬁcantly heat
PBS control solutions (Figure 3c,d, Supporting Informa-
tion, Figure 2). After 3 min of NIR irradiation, one PEG-
NR-dependent heater (device 2) elevated a 100 μg/mL
PEG-NR solution by 20.53 C( 0.68 C, a 10μg/mL PEG-
NR solution by 11.90 C ( 0.44 C, a 1 μg/mL PEG-NR
solution by 4.43 C ( 0.47 C, and a PBS control
solution by 2.57 C ( 0.79 C. Collectively, this ex vivo
characterization helped identify a subset of implanted
NIR light sources to evaluate in an in vivo context.
The ex vivo ﬂuence rate and PEG-NR photothermal
heating measurements, coupled with computational
models for two generic device geometries (i.e., silica
rod and ﬂexible mesh sheet) allowed for progressive
down-selection of candidate devices prior to attempt-
ing plasmonic photothermal therapy in an animal
model. Despite comparable ﬂuence rate modeling
predictions between the rod and mesh sheet, the
various silica rod designs were pursued further be-
cause their material properties and construction
Figure 3. (a) Images of implanted NIR devices 2, 3, 5, and 6 (top to bottom). Infrared thermographic images of PEG-NR and
PBS solutions after NIR exposure with implanted NIR devices. Scale bar: 1 cm. (b) Representative thermographic timecourse
for device 2, illustrating selective heating of PEG-NRs. (c) PEG-NR heating for implanted NIR devices 2, 3, 5, and 6 (left to right)
(n = 3 per group). Error bars, s.e.m. (d) Maximal temperature elevation for multiple PEG-NR concentrations. (n = 3 per group;
***P < 0.001; one-way ANOVA and Tukey post-tests.) Error bars, s.e.m.
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proved able to sustain input powers in the anticipated
range necessary for in vivo photothermal heating. The
6-fold lower measured surface ﬂuence rate compared
to the model prediction illustrated that incorporation
of physical properties of the device would be advanta-
geous for future simulations, and also that future
iterations of the ﬂexible mesh should include design
parameters that can sustain the necessary power
requirements for plasmonic photothermal heating.
Of the silica rod devices with the highest measured
ﬂuence rates, only a subset was able to heat PEG-NR
solutions in a selective and dose-dependent manner.
Those devices which failed to achieve PEG-NR-speciﬁc
heating likely did so due to a combination of subopti-
mal geometric design and the incorporation of highly
absorptive elements. Suboptimal geometries such as
the long, narrow cylindrical design may have resulted
in poorly diﬀused incoming NIR light with inhomoge-
neous emission to the surrounding environment. Such
geometric constraints have been previously observed
in the related ﬁeld of laser-induced interstitial therapy,
where NIR scattering from implanted laser applicators
in part determines the volume of tissue susceptible to
heating therapy.32,33 While the power required for this
ablative therapeutic modality is substantially higher
than that required for plasmonic photothermal ther-
apy, the ability of the implanted device to scatter NIR
light isotropically andminimize heat conduction at the
tissue-device interface is highly dependent on geo-
metric and material design parameters and is impor-
tant for ensuring broad tissue coverage. Incorporating
a metallic cap at the device tip led to heating of both
PEG-NR and control solutions nonselectively, suggest-
ing that the metallic cap absorbed the incident NIR
light to generate heat within the device itself. Such
designs are not suitable for implantation into the
abdominal cavity due to reduced, inhomogeneous
light emission, as well as local coagulation of tissues
in the vicinity of the device tip.33 Limiting the incor-
poration of absorptive elements and improving light
scattering from the device surface would help reduce
the nonspeciﬁc heating observed here. The optimal
implanted NIR device based on ﬂuence rate and
selective PEG-NR heating had a tapered tip design
and a length of∼3 cm, which was among the shortest
of the candidate devices investigated. Future iterations
on silica- or ﬁber optic mesh-based implanted NIR
devices will focus on improved ﬂexibility, isotropic
NIR emission from the device surface, and improved
materials able to sustain a broader range of powers
and thereby reduce the time required to reach the
desired temperature range for plasmonic photother-
mal therapy.
The functionof a silica rod from thePEG-NR-dependent
activator groupwas next assessed in an orthotopicmouse
model of ovarian cancer. The device was implanted into
the abdominal cavity through an approximately 1 cm
midline incision on the ventral surface and connected
to the laser source via ﬁber optic cable (Figure 4a).
To visualize the device inside the abdominal cavity,
computed tomography (CT) imaging was performed.
CT images clearly delineated the implanted device and
revealed its placement relative to abdominal structures
including intestine, abdominal wall, and vertebral
bodies (Figure 4a, Supporting Information, Figure 3).
To investigate the capability and speciﬁcity of the
device to photothermally heat various tissues, the
device was implanted into the abdominal cavity of
animals pretreated with PEG-NRs or control animals
lacking PEG-NRs, and the temperature of ovarian tu-
mor tissue, intestine, and liver was continuously mon-
itored with thermocouples placed at approximately
equal distances (0.30.5 cm) from the implanted
device within each of these tissues (Supporting Infor-
mation, Figure 4). Thermal proﬁling revealed a more
eﬃcient heating process in ovarian tumors, intestines,
and livers of PEG-NR-treated animals relative to control
animals lacking PEG-NRs (Figure 4bd). Modest tem-
perature changes between 2.4 and 3.0 C observed in
tissues lacking PEG-NRs may be attributed to heat
nonspeciﬁcally conducted from the device itself.
In contrast, temperature elevations observed within
the ﬁrst minute of NIR exposure rose signiﬁcantly
steeper for tumors and liver in animals pretreated with
PEG-NRs, while the trend was also increased but not
signiﬁcant for the intestine (Figure 4eg). For tissues
in the PEG-NR group, the maximum temperature
changes for tumor, liver, and intestine were 6.27 C (
2.47 C, 6.51( 1.47 C, and 4.66( 2.49 C, respectively
(Figure 4h). Following PEG-NR photothermal heating,
tissue sections were prepared to assess tissue viability
and any resulting histological changes consistent with
inﬂammatory or necrotic tissue damage. Importantly,
normal tissue histology was observed for intestine,
tumor, and liver by H&E staining (Figure 4i). Further-
more, Ki67-positive immunohistochemical staining
conﬁrmed that these tissues remained actively prolif-
erative after photothermal heating (Figure 4i). Evi-
dence of mild bleeding and coagulation at the device
incision site, however, was noted in some animals
investigated. These studies therefore establish that
an implanted NIR device shown to selectively heat
PEG-NR solutions in an ex vivo setting can likewise heat
tissues containing PEG-NRs deepwithin the abdominal
cavity while not inducing irreversible damage in these
organs.
Plasmonic photothermal therapy and other modal-
ities to heat tumors in the subablative range (ca.
4145 C) have been shown in subcutaneous models
to alter the ﬂow and permeability of tumor vessels and
enhance accumulation of diﬀusion-limited therapeutic
cargoes.3438 To investigate whether NIR irradiation
from the implanted silica rod similarly drove accumu-
lation of therapeutic cargoes in an orthotopic site,
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tumors from NIR-treated and control animals were
studied following administration of doxorubicin-
loaded liposomes and the diagnostic imaging agent
AngioSPARK750 (AS750; core diameter, 2050 nm).
We observed from prior studies that the lower third of
the silica rod dispersed NIR light with high intensity, so
this regionwas used to induce heating in tumors in this
proof-of-principle study. Intraperitoneal tumors from
the quadrant receiving NIR illumination and harvested
3 h after receiving AS750 and PEG-NR/implanted NIR
heating demonstrated elevated macroscopic accumu-
lation of AS750 (Figure 4j). Signiﬁcantly elevated en-
hancements of 3.27 and 11.2 for doxorubicin-loaded
liposomes and AS750, respectively, were measured
in homogenized tumor samples from the PEG-NR/
implanted NIR group relative to control tumors from
animals receiving no PEG-NR/implanted NIR therapy
(Figure 4k). These data suggest that plasmonic-based
Figure 4. (a) Placement of implanted NIR device in a tumor-bearing animal shownmacroscopically, by axial CT scan (R, rod; I,
intestine; V, vertebrate; dashed line outlining body cavity), and 3D-rendered CT scanning. (bd) Thermal proﬁling in the
presenceor absenceof PEG-NRs in (b) ovarian tumors, (c) intestine, and (d) liver. (n=35per group). (eg) Initial temperature
change after 50 s of direct implanted NIR illumination in (e) tumors, (f) intestine, and (g) liver in PEG-NR-treated animals and
controls. Red bar denotes mean value per group. (n = 35, *P < 0.05, unpaired t test). (h) Maximal temperature change
for tumor, liver, and intestine of PEG-NR-treated animals (n = 5 per tissue). Error bars, s.e.m. (i) Histology and Ki-67
immunohistochemical staining of tissues following PEG-NR therapy with implanted NIR device. Scale: 100 μm. (j) Whole-
tumor ﬂuorescence of AngioSPARK750 and (k) quantiﬁcation of doxorubicin-loaded liposomes andAngioSPARK750 in tumor
homogenates from tissues harvested 3 h after injection and PEG-NR/ImplantNIR therapy or injectiononly. (n=1112 tumors,
3 animals per group, **P < 0.01,****P < 0.0001, MannWhitney test) Error bars, s.e.m.
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enhancement of therapeutic cargoes previously ob-
served in subcutaneous tumormodels35may also have
utility for delivering cargoes to tumors in the abdom-
inal cavity.
For in vivo thermographic studies, the liver and
intestine were studied in addition to tumors for several
reasons. First, previous work on the biodistribution of
PEG-NRs has demonstrated a signiﬁcant accumulation
of PEG-NRs in the liver (∼14% ID/g).16 Because of its
high PEG-NR concentration, large size, and proximity to
orthotopic ovarian tumor nodules, the liver poses a
challenge for tumor-speciﬁc photothermal heating in
the abdominal cavity. The temperature elevations ob-
served in the liver were anticipated, and, importantly,
they relaxed to baseline temperatures within several
minutes after the procedures. The intestine, while
accumulating fewer PEG-NRs than the liver, has been
shown to be sensitive to broad elevations in tempera-
ture. This has been observed most notably during
investigations with heated chemotherapy adminis-
tered directly into the abdominal cavity for ovarian
cancer patients.39 In this study, elevations in intestinal
temperature were detected, but no tissue damage or
proliferative defects were observed, and the thermal
eﬀects were more modest than in ovarian tumors or
the liver, which is perhaps representative of diﬀering
PEG-NR concentrations within each of these tissues. A
key advantage of PEG-NRs and plasmonic nanomater-
ials more generally is the ability to “sensitize” tumor
tissue to incident NIR light relative to surrounding
tissues containing fewer PEG-NRs. The ability to locally
deposit heat in desired tissues using plasmonic nano-
materials stands in marked contrast to heated che-
motherapy approaches which cause nonspeciﬁc tem-
perature elevations throughout the entire abdominal
cavity and have been associated with high morbidity
and even mortality.39 In the future, strategies to both
shield nontumor, PEG-NR-rich tissues (e.g., liver) from
implanted NIR light as well as spatially localize thermal
gradients around PEG-NRs via pulsed laser sources
could prove fruitful formitigating any oﬀ-target eﬀects.
CONCLUSIONS
Plasmonic nanomaterial-based therapies that gen-
erate localized heating within tumors hold great pro-
mise for future clinical interventions in oncology, but
novelmethods of deliveringNIR light to deeply located
and distributed solid tumors are needed for tumors
that do not reside superﬁcially beneath the skin. Here,
to overcome the optical limitations of external NIR
irradiation, we propose a possible alternative strategy
using a biocompatible, implanted NIR illumination
device and assess its functionality through computa-
tional modeling, ex vivo characterization, and in vivo
thermographic proﬁling of orthotopic ovarian tumors.
Ray tracing analysis in a simulated mouse model
approximated the degree of NIR light penetration
inﬂuenced by tissue scattering and absorption from
two general device designs, providing a framework for
selecting candidates for further study. These modeling
predictions were validated and further reﬁned by
ex vivo ﬂuence rate and thermographicmeasurements,
as well as in vivo plasmonic photothermal heating of
PEG-NR-containing ovarian tumors and nontumor tis-
sues. We demonstrate that localized plasmonic heat-
ing of ovarian tumors by this method can enhance
accumulation of diagnostic and therapeutic agents
including doxorubicin liposomes in this orthotopic
tumor model. In future studies, it will be valuable to
investigate what therapeutic beneﬁts may be attained
in these deep-seated tumors and the degree to which
they correlate with results obtained from related pre-
clinical models as plasmonic nanomaterials advance
closer to clinical use.
MATERIALS AND METHODS
Synthesis of PEG-NRs. Gold nanorods (GNRs) coated in
PEG were prepared as described previously.16,17 Briefly,
41 nm  10 nm cetyltrimethylammonium (CTAB)-coated GNRs
(Nanopartz) were concentrated ∼100-fold by centrifugation at
15 000 rcf for 30 min, incubated with 5-kDa methyl-PEG-thiol
(Laysan Bio, Inc.) to 100 μM, and dialyzed for at least 24 h against
distilled, deionizedwater in 3500MWCO Slide-A-Lyzer cassettes
(Thermo Scientific). Dialyzed samples were washed in ultrapure
water, filtered through 100-kDa filters (Millipore), and resus-
pended in PBS. PEG-NR solutions were stored at 4 C.
Device Design and Construction. Implanted devices consisted of
silica rods and fiber optic meshes (Rogers Sciences, Inc.). Silica
rods were treated by an optomechanical scoring process to
create varying illumination patterns and light-dispersive coat-
ings. Light emission was incoherent with an exitance of ∼2π
steradians at each illumination surface. Fiber opticmeshes were
encased in medical-grade silicone to provide adhesion, flex-
ibility, and biocompatibility. Meshes were treated in an array
format by an optomechanical scoring process to allow approxi-
mately uniform light emission from the top surface.
Computational Modeling. An approximate anatomicalmodel of
the mouse was developed including liver, intestine, kidney,
stomach, spleen, lungs, vertebrae, and skin using a nudemouse
(female) atlas as a guide (Xenogen). Tissue layers were assigned
indices of refraction, scattering coefficients, and absorption
coefficients. Implanted NIR devices (silica rod, flexible mesh)
were simulated in this three-dimensional anatomical model
using Zemax and TracePro software. Each simulation performed
consisted of 1  104 distinct ray tracings. NIR illumination from
the silica rod was modeled as 1  104 ray tracings across the
device's entire length and diameter, while illumination from the
fiber optic mesh was modeled as 1  104 ray tracings emitted
from the top and bottom surfaces of the mesh. The surfaces for
both devices were modeled with a lambertian reflectance
profile (1 W, 808 nm).
Fluence Rate Measurements. Implanted NIR devices were di-
rectly coupled to an 810 nm continuous diode laser source
(Visotek) through an SMA-threaded glass fiber optic cable
(0.4 mm diameter). Fluence rate measurements were recorded
on an optical power and energy meter with an S121C silicon
photodiode power sensor (4001100 nm, 500 mW) (Thorlabs).
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Measurements were obtained at 808 nm at multiple distances
and input currents.
Ex vivo Thermographic Profiling. Solutions of PEG-NRs (0, 1, 10,
and 100 μg/mL) were irradiated by implanted NIR devices for
3 min. Maximal surface temperatures of PEG-NR solutions were
monitored continuously by infrared thermography (Thermacam
S60, FLIR). Each concentration of PEG-NRs was identically ex-
posed to the 810 nm laser illumination. All conditions reported
were measured in triplicate.
In Vivo Imaging. All animal studies were approved by the MIT
Committee on Animal Care. Computed tomographic (CT) ima-
ging on animals with implanted NIR devices was performed on
an eXplore CT120-wholemouseMicroCT system (GE Healthcare).
Image analysis for anatomic measurements and three-
dimensional rendering was performed with MicroView soft-
ware (GE Healthcare).
In Vivo Thermographic Profiling. Female NCR nude mice at ∼4
weeks of age (Taconic) received an intraperitoneal injection
of ∼5  105 OVCAR8 human ovarian cancer cells expressing
firefly luciferase. At 46 weeks following implantation, the
establishment of tumors was confirmed on the whole-animal
IVIS spectrum-bioluminescent and fluorescent imaging system
(Xenogen). Tumor-bearing animals received either an intrave-
nous injection of PEG-NRs (100 μL; ∼14 mg Au/kg) or no injec-
tion for the control group; after vascular clearance (∼48 h),
animals were anesthetized and a midline incision through the
skin and abdominal wall was made for implantation of the silica
rod NIR device under study. To assess tissue-specific heating
properties, the implanted NIR device was independently posi-
tioned in proximity to the liver, intestine, and ovarian tumors
within the abdominal cavity. K-type fiberglass thermocouples
(National Instruments) were placed adjacent to each tissue and
equidistantly from the NIR device (ca. 0.30.5 cm) to mini-
mize nonspecific direct heating effects from the device.
Implanted devices were connected via fiber optic cable to
a continuous 810 nm laser source (Visotek) during a five
minute heating period per tissue. Thermocouple tempera-
ture signals were integrated on a portable DAQ thermo-
couple module (NI USB-9211A, National Instruments) and
recorded at 2 Hz with NI-DAQmx and LabView software
during the five minute heating window. Thermographic
profiles were assembled and statistically analyzed with
Prism 5 software (GraphPad).
Histology. Harvested tissues were fixed in 4% paraformalde-
hyde overnight at 4 C prior to paraffin embedding. Standard
hematoxylin and eosin (H&E) staining was performed on sec-
tions of tumor, liver, and intestine. Immunohistochemical stain-
ing for the cell proliferation protein Ki67 was performed with
primary antibody rabbit antihuman Ki67 (1:100, EMD Millipore).
IHC with antigen retrieval was performed on the LabVision
Autostainer 360 Immunohistochemical Stainer (Thermo
Scientific).
In Vivo Quantification of Cargo. Tumor-bearing animals received
an intravenous coinjection of doxorubicin-loaded liposomes
(8mgDox/kg) and AngioSPARK750 (100μL in PBS) (Perkin-Elmer).
The silica rod was implanted as described and positioned in
proximity to multiple tumor nodules within a specified quad-
rant of the abdomen. Each animal received continuous NIR light
irradiation (810 nm) for 30 min and the abdominal wall and skin
were sutured prior to recovery. Three hours after the procedure,
tumors were harvested and AS750 fluorescence within whole
tumors was imaged on an NIR imaging system (LICOR Odyssey).
Tumors wereweighed and homogenized in 1.0mL of extraction
buffer (70% EtOH, 0.3 N HCl) using an automated tissue homo-
genizer (gentleMACS Octo Dissociator, Miltenyi Biotec). Super-
natants were measured on LICOR platform for AS750 and a
fluorescence microplate reader (Molecular Devices, Spectra-
MAX GeminiEM) for doxorubicin fluorescence. For each group,
the fluorescence of 12 individual tumor supernatants obtained
from three mice per group was normalized by tissue weight
prior to analysis.
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